Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;29(2):137-143.
doi: 10.21147/j.issn.1000-9604.2017.02.06.

Insights into gastric neuroendocrine tumors burden

Affiliations

Insights into gastric neuroendocrine tumors burden

Taíssa Maíra Thomaz Araújo et al. Chin J Cancer Res. 2017 Apr.

Abstract

Type 1 gastric neuroendocrine tumors (gNETs) are usually small lesions, restricted to mucosal and sub-mucosal layers of corpus and fundus, with low aggressive behavior, for the majority of cases. Nevertheless, some cases present aggressive behavior. The increasing incidence of gNETs brings together a new relevant problem: how to identify potentially aggressive type 1 gNETs. The challenging problem seems to be finding out signs or features able to predict potentially aggressive cases, allowing a tailored approach, since the involved societies dedicated to provide guidelines for management of these neoplasms apparently failed in producing staging systems able to accurately predict prognosis of these tumors. Additionally, it is also important to try to find out explanations for increasing incidence, as well as to identify potential targets aiming to reach better control of this neoplasia. Here, we discuss potential pathways implicated in aggressive behavior, as well as new strategies to improve clinical management of these tumors.

Keywords: epidemiology; gNETs; gastrin receptor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12:153–72. [Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-72.] - PubMed
    1. Modlin IM, Kidd M, Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg. 2002;168:669–83. [Modlin IM, Kidd M, Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg 2002;168:669-83.] - PubMed
    1. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol. 2005;17:1–6. [Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol 2005;17:1-6.] - PubMed
    1. Chen WF, Zhou PH, Li QL, , et al. Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. Scientific World Jounal. 2012;2012:869769. [Chen WF, Zhou PH, Li QL, et al. Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. Scientific World Jounal 2012;2012:869769.] - PMC - PubMed
    1. Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo) 2011;66:1671–5. [Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo) 2011;66:1671-5.] - PMC - PubMed

LinkOut - more resources